REFERENCES
- Jeanette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 2003;63:1164–1177.
- Savage CO, Harper L, Holland M. New findings in pathogenesis of antineutrophil cytoplasm antibody-associated vasculitis. Curr Opin Rheumatol. 2002;14:15–22.
- Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med. 2004;117:39–50.
- Chen M, Yu F, Wang SX, . Antineutrophil cytoplasmic autoantibody-negative pauci-immune crescentic glomerulonephritis. J Am Soc Nephrol. 2007;18:599–605.
- Weidanz F, Day CJ, Hewins P, . Recurrences and infections during continuous immunosuppressive therapy after beginning dialysis in ANCA-associated vasculitis. Am J Kidney Dis. 2007;50:36–46.
- Hoffman GS, Kerr GS, Leavitt RY, . Wegener’s granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116:488–498.
- Gera M, Griffin MD, Specks U, . Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosuppression. Kidney Int. 2007;71:1296–1301.
- RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–232.
- Mukhtyar C, Lee R, Brown D, . Modification and validation of the Birmingham vasculitis activity score (version 3). Ann Rheum Dis. 2009;68:1827–1832.
- Hagen C, Daha MR, Hermans J, . Diagnostic value of standardized assays for antineutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int. 1998;53:747–753.
- De Groot K, Harper L, Jayne DRW, . Pulse versus daily oral cyclophosphamide or induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150:670–680.
- Jayne D, Rasmussen N, Andrassy K, . A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36–44.
- Cox DR. Regression models and life table tables. J R Stat Soc. 1972;34:187–219.
- Hogan SL, Nachman PH, Wilkman AS, . Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7:23–32.
- Weidner S, Geuss S, Hafezi-Rachti S, . ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant. 2004;19:1403–1411.
- Harper L, Savage CO. ANCA-associated renal vasculitis at the end of the twentieth century—a disease of older patients. Rheumatology. 2005;44(4):495–501.
- Vassallo M, Shepherd RJ, Iqbaal P, . Age-related variations in presentation and outcome in Wegener’s granulomatosis. J R Coll Physicians Lond. 1997;31:396–400.
- Lionaki S, Hogan SL, Jennette CE, . The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int. 2009;76:644–651.
- Luqmani RA, Bacon PA, Beaman M, . Classical versus non-renal Wegener’s granulomatosis. Q J Med. 1994;87:161–167.
- Merino JL, Galeano C, Espejo B, . A retrospective study on outcome of microscopic polyangiitis in chronic renal replacement therapy. Nephrol Dial Transplant. 2011;26(4):1360–1366.
- Itabashi M, Takei T, Yabuki Y, . Clinical outcome and prognosis of anti-neutrophil cytoplasmic antibody-associated vasculitis in Japan. Nephron Clin Pract. 2010;115(1):c21–c27.
- Mahr A, Girard T, Agher R, . Analysis of factors predictive of survival based on 49 patients with systemic Wegener’s granulomatosis and prospective follow-up. Rheumatology (Oxford). 2001;40:492–498.
- Cruz BA, Ramanoelina J, Mahr A, . Prognosis and outcome of 26 patients with systemic necrotizing vasculitis admitted to the intensive care unit. Rheumatology (Oxford). 2003;42(10):1183–1188.